Table 1 Amounts of study drug and number of cycles (Gordon et al, 2001; Smith et al, 2002)

From: Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

 

Total mg drug used

Mg per patient

Total cycles

Cycles per patient

Total doses

PLD

     

(n=239)

94 447

395.18

1164

4.87

1164

Topotecan

     

(n=235)

15 653

66.60

1349

5.74

6673

  1. PLD=pegylated liposomal doxorubicin hydrochloride.